Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APPTg2576 mouse model of Alzheimer's disease

Neurobiology of Learning and Memory

Volumn 95, Issue 1, 2011, Pages 64-72

  Bardgett, Mark E ^a   Davis, Natasha N ^a   Schultheis, Patrick J ^a   Griffith, Molly S ^a  

^a NORTHERN KENTUCKY UNIVERSITY   (United States)

Author keywords

Amyloid precursor protein; Cognitive enhancement; Histamine; Locomotor activity; Object recognition; Swim maze

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CIPROXIFAN; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; IMIDAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HYPERACTIVITY; LATENT PERIOD; LOCOMOTION; MALE; MAZE TEST; MOUSE; NEUROMODULATION; NONHUMAN; PATTERN RECOGNITION; SWIMMING; TASK PERFORMANCE; TRANSGENIC MOUSE; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; COGNITION; DRUG EFFECT; GENETICS; GENOTYPE; HYPERKINESIA; MEMORY DISORDER; MOTOR ACTIVITY; RECOGNITION;

AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; COGNITION; GENOTYPE; HISTAMINE ANTAGONISTS; HYPERKINESIS; IMIDAZOLES; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; RECOGNITION (PSYCHOLOGY);

EID: 78651243869     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nlm.2010.10.008     Document Type: Article

References (47)

1. Bacciottini L., Passani M.B., Giovannelli L., Cangioli I., Mannaioni P.F., Schunack W., et al. Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: A dual-probe microdialysis study in the freely moving rat. European Journal of Neuroscience 2002, 15:1669-1680.
2. Bardgett M.E., Baum K.T., O'Connell S.M., Lee N.M., Hon J.C. Effects of risperidone on locomotor activity and spatial memory in rats with hippocampal damage. Neuropharmacology 2006, 51:1156-1162.
3. Bardgett M.E., Jacobs P.S., Jackson J.L., Csernansky J.G. Kainic acid lesions enhance locomotor responses to novelty, saline, amphetamine, and MK-801. Behavioural Brain Research 1997, 84:47-55.
4. Bardgett M.E., Points M., Roflow J., Blankenship M., Griffith M.S. Effects of the H3 receptor antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration. Psychopharmacology 2009, 205:589-597.
5. 3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (Dizocilpine) in rats. Neuropharmacology 2010, 59:492-502.
6. Bembenek S.D., Keith J.M., Letavic M.A., Apodaca R., Barbier A.J., Dvorak L., et al. Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorganic & Medicinal Chemistry 2008, 16:2968-2973.
7. Bernaerts P., Lamberty Y., Tirelli E. Histamine H3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behavioural Brain Research 2004, 154:211-219.
8. Berry S.D., Seager M.A. Hippocampal theta oscillations and classical conditioning. Neurobiology of Learning and Memory 2001, 76:298-313.
9. Bonaventure P., Letavic M., Dugovic C., Wilson S., Aluisio L., Pudiak C., et al. Histamine H3 receptor antagonists: From target identification to drug leads. Biochemical Pharmacology 2007, 73:1084-1096.
10. Brabant C., Alleva L., Grisar T., Quertemont E., Lakaye B., Ohtsu H., et al. Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice. role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology 2009, 202:673-687.
11. Clapham J., Kilpatrick G.J. Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: Evidence for the possible existence of H3 receptor subtypes. British Journal of Pharmacology 1992, 107:919-923.
12. Clapham J., Kilpatrick G.J. Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. European Journal of Pharmacology 1994, 259:107-114.
13. David H.N., Abraini J.H. Differential modulation of the D1-like- and D2-like dopamine receptor-induced locomotor responses by group II metabotropic glutamate receptors in the rat nucleus accumbens. Neuropharmacology 2001, 41:454-463.
14. de Bruin J., Sanchez-Santed F., Heinsbroek R., Donker A., Postmes P. A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: Evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Research 1994, 652:323-333.
15. Dong H., Goico B., Martin M., Csernansky C.A., Bertchume A., Csernansky J.G. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 2004, 27:601-609.
16. Dong H., Martin M.V., Chambers S., Csernansky J.G. Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. Journal of Comparative Neurology 2007, 10:311-321.
17. Dong H., Yuede C.M., Yoo H.S., Martin M.V., Deal C., Mace A.G., et al. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience 2008, 155:154-163.
18. Esbenshade T.A., Fox G.B., Cowart M.D. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Molecular Interventions 2006, 6:77-88.
19. Esbenshade T.A., Krueger K.M., Miller T.R., Kang C.H., Denny L.I., Witte D.G., et al. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. Journal of Pharmacological and Experimental Therapeutics 2003, 305:887-896.
20. España J., Giménez-Llort L., Valero J., Miñano A., Rábano A., Rodriguez-Alvarez J., et al. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biological Psychiatry 2010, 67:513-521.
21. Ferrada C., Ferré S., Casadó V., Cortés A., Justinova Z., Barnes C., et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008, 55:190-197.
22. Fox G.B., Esbenshade T.A., Pan J.B., Radek R.J., Krueger K.M., Yao B.B., et al. Pharmacological properties of ABT-239 [4-2-{2-[2R-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-ylbenzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 2005, 313:176-190.
23. Fox G.B., Pan J.B., Radek R.J., Lewis A.M., Bitner R.S., Esbenshade T.A., et al. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. Journal of Pharmacology and Experimental Therapeutics 2003, 305:897-908.
24. Fu Q., Dai H., He P., Hu W., Fan Y., Zhang W., et al. The H3 receptor antagonist clobenpropit protects against Abeta42-induced neurotoxicity in differentiated rat PC12 cells. Pharmazie 2010, 65:257-260.
25. Galici R., Boggs J.D., Aluisio L., Fraser I.C., Bonaventure P., Lord B., et al. JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 2009, 56:1131-1137.
26. Gil-Bea F.J., Aisa B., Schliebs R., Ramírez M.J. Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behavioral Neuroscience 2007, 121:340-344.
27. Golub M.S., Germann S.L., Mercer M., Gordon M.N., Morgan D.G., Mayer L.P., et al. Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of Aging 2008, 29:1512-1523.
28. Hajós M., Siok C.J., Hoffmann W.E., Li S., Kocsis B. Modulation of hippocampal theta oscillation by histamine H3 receptors. Journal of Pharmacology and Experimental Therapeutics 2008, 324:391-398.
29. Hsiao K., Chapman P., Nilsen S., Eckmanm C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
30. King D.L., Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiology & Behavior 2002, 75:627-642.
31. Lalonde R., Lewis T.L., Strazielle C., Kim H., Fukuchi K. Transgenic mice expressing the betaAPP695SWE mutation: Effects on exploratory activity, anxiety, and motor coordination. Brain Research 2003, 977:38-45.
32. Le Cudennec C., Faure A., Ly M., Delatour B. One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain & Behavior 2008, 7(supplement 1):83-91.
33. Le S., Gruner J.A., Mathiasen J.R., Marino M.J., Schaffhauser H. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 2008, 325:902-909.
34. Ligneau X., Landais L., Perrin D., Piriou J., Uguen M., Denis E., et al. Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochemical Pharmacology 2007, 73:1215-1224.
35. Ligneau X., Lin J., Vanni-Mercier G., Jouvet M., Muir J.L., Ganellin C.R., et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 1998, 287:658-666.
36. Ligneau X., Perrin D., Landais L., Camelin J.C., Calmels T.P., Berrebi-Bertrand I., et al. BF2.649 [1-{3-[3-4-Chlorophenylpropoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. Journal of Pharmacology and Experimental Therapeutics 2007, 320:365-375.
37. Lindner M., Plone M., Schallert T., Emerich D. Blind rats are not profoundly impaired in the reference memory Morris water maze and cannot be clearly discriminated from rats with cognitive deficits in the cued platform task. Cognitive Brain Research 1997, 5:329-333.
38. Medhurst A.D., Atkins A.R., Beresford I.J., Brackenborough K., Briggs M.A., Calver A.R., et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. Journal of Pharmacology and Experimental Therapeutics 2007, 321:1032-1045.
39. Morisset S., Pilon C., Tardivel-Lacombe J., Weinstein D., Rostene W., Betancur C., et al. Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: Selective involvement of the D(2) and not D(3) receptor. Journal of Pharmacological & Experimental Therapeutics 2002, 300:621-628.
40. Pillot C., Heron A., Cochois V., Tardivel-Lacombe J., Ligneau X., Schwartz J.C., et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002, 114:173-193.
41. Rizk A., Curley J., Robertson J., Raber J. Anxiety and cognition in histamine H3 receptor-/-mice. European Journal of Neuroscience 2004, 19:1992-1996.
42. Southam E., Cilia J., Gartlon J.E., Woolley M.L., Lacroix L.P., Jennings C.A., et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology 2009, 201:483-494.
43. Tabuchi M., Yamaguchi T., Iizuka S., Imamura S., Ikarashi Y., Kase Y. Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. Journal of Ethnopharmacology 2009, 122:157-162.
44. Taglialatela G., Hogan D., Zhang W.R., Dineley K.T. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behavioural Brain Research 2009, 200:95-99.
45. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. Journal of Neuroscience 2002, 22:1858-1867.
46. White I.M., Whitaker C., White W. Amphetamine-induced hyperlocomotion in rats: Hippocampal modulation of the nucleus accumbens. Hippocampus 2006, 16:596-603.
47. Yokoyama F., Yamauchi M., Oyama M., Okuma K., Onozawa K., Nagayama T., et al. Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: A comparative study with antidepressants and benzodiazepine anxiolytic. Psychopharmacology 2009, 205:177-187.